Exploring in vitro efficacy of rCHAPk with antibiotic combinations, and promising findings of its therapeutic potential for clinical-originated MRSA wound infection
 
Yazarlar (7)
Semra Taşdurmazlı Yıldız Teknik Üniversitesi, Türkiye
Doç. Dr. İrfan ÇINAR Kastamonu Üniversitesi, Türkiye
Murat Karameşe Kafkas Üniversitesi, Türkiye
Selina Aksak Karameşe Kafkas Üniversitesi, Türkiye
Prof. Dr. Elif Çadırcı Ataturk University, Faculty Of Medicine, Türkiye
Luis D. R. Melo Universidade Do Minho, Portekiz
Tülin Özbek Yıldız Teknik Üniversitesi, Türkiye
Makale Türü Açık Erişim Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı International Journal of Biological Macromolecules (Q1)
Dergi ISSN 0141-8130 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 01-2025
Cilt / Sayı / Sayfa 296 / 1 / 13–0 DOI 10.1016/j.ijbiomac.2025.139630
Makale Linki https://hdl.handle.net/1822/94658
Özet
The increasing threat of antimicrobial-resistant bacteria, particularly Staphylococcus aureus, which rapidly develops multidrug resistance and commonly colonizes wound surfaces, demands innovative strategies. Phage-encoded endolysins offer a dual-purpose approach as topical therapies for infectious skin wounds and synergistic agents to reduce high-dose antibiotic dependence. This study explores recombinant CHAPk (rCHAPk), efficiently synthesized within 3 h, displaying broad-spectrum antibacterial activity against 10 Gram-positive strains, including resistant variants, with rapid bactericidal kinetics. Application of 10 μg of rCHAPk reduced OD600 by 0.4 within 5 min against a clinical methicillin-resistant S. aureus (MRSA) strain. Combining rCHAPk (1.875 μg/mL) with oxacillin/vancomycin lowered their minimum bactericidal concentrations to 1 μg/mL from initial values over 64 μg/mL and 32 μg/mL …
Anahtar Kelimeler
Endolysin rCHAPk | Endolysin-antibiotic synergism | MRSA-infected in vivo wound model